342 related articles for article (PubMed ID: 22029513)
1. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Manuel O; Perrottet N; Pascual M
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
Asberg A; Rollag H; Hartmann A
Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
6. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA; Park JM
Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
[TBL] [Abstract][Full Text] [Related]
10. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
12. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
Kroes AC
Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
[TBL] [Abstract][Full Text] [Related]
13. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
14. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
16. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
17. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
18. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
Reusser P
Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
20. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
